Ipsen appoints new Exec VP and Chief Medical Officer
pharmafile | January 17, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | appointment, ipsen, pharma
Ipsen has named Dr Steven Hildemann as its new Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance.
In his new role, which begins on 1 March 2020 and will be based in Paris, he will report directly to Ipsen CEO Aymeric Le Chatelier. His remit will include the provision of medical strategy to the company’s scientific, clinical and business teams, while also working in tandem with its R&D operations to design and direct clinical trials efforts to generation of post-launch data.
In addition, he has also been welcomed to serve on the company’s executive leadership team, through which he will help steer management and strategic direction of the company.
Dr Hildemann joins Ipsen from his most recent role where he served Merck Gruppe for five years as its Chief Medical Officer, Senior Vice President, Head of Global Medical Affairs and Global Patient Safety. Further back in his career, he also held leadership roles at Amgen, Pharmacia-Pfizer and Schering-Plough-MSD.
“As we advance as a leading global biopharmaceutical company focused on innovation and specialty care, it is my great pleasure to appoint Dr Hildemann to lead Ipsen’s Global Medical Affairs, Patient Affairs and Pharmacovigilance organisations through patient-centric leadership, sound medical governance and business conduct,” commented Le Chatelier.
“With over 20 years of service in the pharmaceutical industry and 10 years as a physician-scientist in academic medicine, he brings a wealth of experience in medical affairs, clinical operations and patient safety from major global biopharmaceutical companies,” he continued. “Dr Hildemann will play a crucial role in delivering on our global medical and patient safety strategy, engaging in structured, ethical and high-quality dialogue with patients, external and internal stakeholders throughout the entire life-cycle of Ipsen’s portfolio.”
Related Content
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …
Ipsen’s Iqirvo approved for use in NHS Scotland to treat rare liver disease
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsen’s Iqirvo (elafibranor) in NHS …
